Regulatory FAQs and common concerns for cell and gene therapy raw and starting materials

In cell and gene therapy, materials matter. Misconceptions, misunderstandings, and misinterpretations can potentially have damaging ramifications for advancement in therapy development, manufacturing, and commercialization.

In this on-demand webinar, we aim to debunk popular myths, provide practical guidance based upon long experience in the field, and clarify key regulatory considerations and requirements across the cell and gene therapy raw and starting materials area.

Complete the form below to listen to our webinar, and receive a white paper on:

  • Troubleshooting misuse of terminology and its repercussions
  • Where do your materials come from and why is it important to know?
  • Raw materials qualification and certification
  • Raw material risk assessment
  • Source or starting material testing
  • Raw material supplier selection and partnering strategy

Kasey Kime

Senior Manager, Regulatory Affairs Clinical and Compliance Life Science Solutions, Thermo Fisher Scientific

Kasey has fifteen years of global quality and regulatory affairs experience in Life Sciences. She is part of Thermo Fisher Scientific’s regulatory affairs division and is overseeing regulatory compliance of technologies developed for cell and gene therapy applications. Her areas of expertise include raw material risk assessment for biopharmaceutical development and regulatory compliance of instruments and consumables developed for automating cell and gene therapy manufacturing. Kasey holds a Bachelor's Degree in Medical Laboratory Science and post graduate degrees in both Microbiology and Quality Systems Management.


Jerrod Denham

Principal, Dark Horse Consulting Group

Over the past two decades, Jerrod has led process engineering, development, and manufacturing teams within several biotechnology companies developing cell and gene therapy products. At Dark Horse Consulting, he advises biotechnology companies on upstream and downstream process engineering, manufacturing, and regulatory through all phases of manufacturing, from the pre-clinical to commercial stages. Utilizing his specialized skills in Lean Six Sigma, formalized root cause analysis, statistical data analysis, design of experiments, technology transfer and facility design, he has solved problems relating to CMC of both cell and gene therapy products.


Christopher Bravery

Consulting Regulatory scientist, Advbiols Ltd

Christopher founded Advbiols Ltd at the end of 2009 in order to focus his activities within the Regenerative Medicine sector. Advbiols Ltd provides EU regulatory services to the regenerative medicine industry in addition to business and regulatory research and analysis to identify and focus on the real barriers to commercialization of regenerative medicine. Christopher has a PhD in xenotransplantation immunology and spent 8 years in biotech (Imutran Ltd, A Novartis Pharma AG Co. and Intercytex) before joining the MHRA as a quality (CMC) assessor (biologicals and biotechnology unit). During this time Christopher was involved with national implementation of the new Advanced Therapies Regulation and also involved through his participation in the CHMP’s cell products working party (CPWP) in implementation at the EMA level including drafting guidelines.